4,325 reports of this reaction
3.4% of all AZITHROMYCIN DIHYDRATE reports
#3 most reported adverse reaction
DYSPNOEA is the #3 most commonly reported adverse reaction for AZITHROMYCIN DIHYDRATE, manufactured by Aurobindo Pharma Limited. There are 4,325 FDA adverse event reports linking AZITHROMYCIN DIHYDRATE to DYSPNOEA. This represents approximately 3.4% of all 126,693 adverse event reports for this drug.
Patients taking AZITHROMYCIN DIHYDRATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among AZITHROMYCIN DIHYDRATE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for AZITHROMYCIN DIHYDRATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 4,325 FDA reports for AZITHROMYCIN DIHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.4% of all adverse event reports for AZITHROMYCIN DIHYDRATE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking AZITHROMYCIN DIHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.